Founding Note: Biological Constants Are Not Held Forever
Published May 2026
The Gap
The first BioConst problem is not a promise. It is drift.
A body can spend decades holding temperature, blood chemistry, bone remodeling, immune repair, hair cycling, and tissue renewal inside narrow operating bands. Then the bands start to move. Some changes are visible. Some show up first as bloodwork, scans, recovery time, or the quiet fact that repair takes longer than it used to. BioConst begins there: aging as the slow loss of biological constants.
This is a research discussion, not medical advice. BioConst does not diagnose, recommend interventions, or offer treatment plans.
The scale is large enough to justify discipline. The World Health Organization reports that the global population aged 60 years or older was 1 billion in 2020, is projected to reach 1.4 billion in 2030, and 2.1 billion in 2050. The same WHO fact sheet projects the population aged 80 years or older to reach 426 million in 2050. Source: WHO, Ageing and health.
Those numbers are often treated as a retirement, care, or pension problem. BioConst treats them first as a biology problem. Longer life without stable repair creates a widening zone between being alive and being well. The practical question is not whether aging can be made into a slogan. It is which set-points fail, how early they fail, which mechanisms are upstream, and which claims survive contact with human evidence.
Why This Matters Now
The field has become specific enough to track without pretending it is settled.
In 2023, the expanded Hallmarks of Aging framework described 12 hallmarks, including genomic instability, loss of proteostasis, disabled macroautophagy, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, chronic inflammation, and dysbiosis. Source: Hallmarks of aging: An expanding universe.
That list matters because it lets BioConst avoid a common error: treating "anti-aging" as one category. A senolytic claim is not the same as a proteostasis claim. An epigenetic reprogramming experiment is not the same as a nutrient-sensing intervention. A mouse lifespan result is not the same as a human functional endpoint. The first job is classification.
There are also early human signals that need careful handling. A 2019 EBioMedicine pilot of dasatinib plus quercetin in idiopathic pulmonary fibrosis listed 14 participants, used an intermittent three-week protocol, and reported feasibility measures in an open-label design. Source: PubMed 30616998. That is useful evidence for an evidence tracker. It is not evidence that the public should copy a protocol.
Clinical-trial records are another useful feed because they force claims into protocol form. NCT05422885 studies dasatinib plus quercetin in older adults at risk for Alzheimer's disease and frames the work around safety and feasibility. Source: ClinicalTrials.gov NCT05422885. BioConst will track records like this as protocol evidence, not as lifestyle advice.
What BioConst Will Study
BioConst starts with four questions.
First: where does repair capacity fail as a system rather than as an isolated disease label? Bone remodeling, lipid regulation, immune response, follicle cycling, and tissue renewal all provide observable ways to think about set-point drift. A useful note must say which mechanism it is discussing and which measurement would change if the mechanism mattered.
Second: which interventions have human evidence, and what kind? The evidence tracker will separate in vitro work, animal work, human pilot data, randomized human studies, and approved uses for non-aging indications. The label matters because public discussion often compresses these tiers into one excitement level.
Third: which endpoints are meaningful? A biomarker can be useful without being sufficient. A functional endpoint can matter even when it is narrower than the story people want to tell. BioConst will mark whether a source reports feasibility, biomarker movement, functional outcomes, disease endpoints, or only a mechanism hypothesis.
Fourth: where are the safety boundaries? The tracker will not hide the difference between a dietary pattern, a prescription drug, a gene-expression experiment, and a cell-state intervention. If an item requires clinician context, that belongs in the first line of the record.
Our Approach
BioConst is built as an evidence ledger before it is a publication surface.
The initial tool is the aging intervention evidence tracker: intervention, mechanism, evidence tier, claim boundary, safety boundary, and source. The first entries cover dasatinib plus quercetin, rapamycin-class mTOR inhibition, partial cellular reprogramming, and proteostasis or macroautophagy support as a framework tag. Each item is constrained by source links and a claim boundary.
The editorial rule is simple: a note should become less vague as it becomes more ambitious. If an article says a mechanism matters, it should name the mechanism. If it says an intervention worked, it should say in what organism, with what endpoint, over what duration, and under what design. If it mentions humans, it should say whether the source is a trial record, an open-label pilot, a randomized trial, or an approved clinical indication.
BioConst does not need loud promises. It needs a durable map of biological drift and evidence quality. The first question remains open: which biological constants fail early enough, measurably enough, and safely enough to become real repair targets?